Adempas - (0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral)

Generic Name	Riociguat	**Innovator**	Bayer
Dosage	0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	None
Indication	Indicated for Treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.